Thanks to an increase in experienced compliance officers, settlements and court judgments between pharmaceutical manufacturers and the federal and state governments are shrinking. While there are many possible theories for the reduction, we would like to think it’s thanks to pharmaceutical compliance officers.
As some of our readers may recall that in late 2012, Public Citizen published a study of all the key financial settlements and court judgments between pharmaceutical manufacturers and the federal and state governments from 1991 through July 18, 2012. At the time of that report’s publication, over $30 billion was paid by the pharmaceutical industry to settle allegations of numerous violations, including alleged off-label marketing and defrauding of Medicare and Medicaid.
Read Full Article in the July 2016 Issue of Life Science Compliance Update